Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression

Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression

September 26, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)Подробнее

September 26, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic LandscapeПодробнее

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic Landscape

How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLCПодробнее

How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

S1 Episode 3: Immunotherapy and Lung Cancer TreatmentПодробнее

S1 Episode 3: Immunotherapy and Lung Cancer Treatment

First line pembrolizumab in PD-L1 TPS 90%+ NSCLCПодробнее

First line pembrolizumab in PD-L1 TPS 90%+ NSCLC

How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLCПодробнее

How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

Updates in Oncology 2021 || 30th August 2021Подробнее

Updates in Oncology 2021 || 30th August 2021

2020 Evolution | Lung Cancer Case PresentationПодробнее

2020 Evolution | Lung Cancer Case Presentation

ESMO 2020: Lung cancer latestПодробнее

ESMO 2020: Lung cancer latest

Novel therapy for Lung Cancer: From targeted therapy to immuno-therapy and back again!Подробнее

Novel therapy for Lung Cancer: From targeted therapy to immuno-therapy and back again!

Martin Reck:Подробнее

Martin Reck:

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

How pembrolizumab will change the management of advanced lung cancerПодробнее

How pembrolizumab will change the management of advanced lung cancer